The Interventional Pharmacoeconomic Toolbox Panel Discussion

First International Summit on Interventional Pharmacoeconomics

David A. Hyman, MD, JD, on Inclusive Shared Savings

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Feb

Today In Oncology

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

ASH 2025: Highlights in Relapsed/Refractory Multiple Myeloma

Oncolytic Virus Triggers Immune System Against Glioblastoma Cells

Adjuvant Durvalumab in Resected Early-Stage NSCLC

FDA Approves Labeling Changes to Menopausal Hormone Therapy Products

Young-Onset Pancreatic Cancer Can Alcohol Consumption Raise Risk